Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
about
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsSatraplatin: leading the new generation of oral platinum agentsRHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.Castration-resistant prostate cancer: new science and therapeutic prospects.Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.
P2860
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
@en
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
@nl
type
label
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
@en
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
@nl
prefLabel
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
@en
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
@nl
P2860
P1476
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
@en
P2093
Andrew J Armstrong
Daniel J George
P2860
P304
P577
2007-10-01T00:00:00Z